JNK

c-Jun N-terminal kinase

JNK

JNK Isoform Specific Products:

JNK Isoform Comparison

JNK Related Products (275)
Antibodies (16)
JNK Isoform Comparison

By Effects:	Controls (3) Inhibitors (193) Agonists (2) Degrader (1) Activators (52) Modulator (1) Inducers (4)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-N7046

Silybin B	Inhibitor	99.90%
Silybin B (Silibinin B) is an orally active amyloid-β aggregation inhibitor and ATR pathway activator, that can cross the blood-brain barrier. Silybin B inhibits Aβ fibril formation and promotes amorphous aggregate formation, while activating the ATR-mediated DNA damage repair pathway and inhibiting JNK/p38 MAPK signaling. Silybin B can reduce Cisplatin (HY-17394)-induced neuronal DNA damage and apoptosis. Silybin B has anti-oxidative stress, cell cycle regulation and neuroprotective activities. Silybin B is mainly used in the study of Alzheimer's disease and Cisplatin chemotherapy-related neurotoxicity.

HY-105935

Keracyanin chloride	Inhibitor	99.90%
Keracyanin chloride inhibits NF-κB/FAK/MAPK signaling pathway. Keracyanin chloride exhibits antioxidant, anti-inflammatory and hypoglycemic effects, and is orally active.

HY-15881

TCS JNK 5a	Inhibitor	99.40%
TCS JNK 5a is a potent JNK3 inhibitor with a pIC₅₀ of 6.7. TCS JNK 5a also inhibits JNK2 with a pIC₅₀ of 6.5.

HY-B1014

Acenocoumarol	Inhibitor	99.87%
Acenocoumarol is an anticoagulant that functions as a Vitamin K antagonist. Acenocoumarol inhibits MAPK/ERK/JNK signaling pathway, reduces the nuclear translocation of NF-κB p65, activates Akt/GSK3β signaling pathway. Acenocoumarol induces apoptosis in cell A549, arrests cell cycle at S phase.

HY-P1190

c-JUN peptide	Inhibitor	99.25%
c-JUN peptide is a cell-permeable c-JUN-JNK interaction inhibitor. c-JUN peptide inhibits serum-induced c-Jun phosphorylation. c-JUN peptide induces apoptosis.

HY-N1504

Loureirin B	Inhibitor	99.16%
Loureirin B, a flavonoid extracted from Dracaena cochinchinensis, is an inhibitor of plasminogen activator inhibitor-1 (PAI-1), with an IC₅₀ of 26.10 μM; Loureirin B also inhibits K_ATP, the phosphorylation of ERK and JNK, and has anti-diabetic activity.

HY-N1941

Isosinensetin	Inhibitor	99.90%
Isosinensetin is a flavonoid compound and an inhibitor of HIV-1 protease and PTP1B (IC₅₀: 2.61 µM; K_i: 0.92 µM). Isosinensetin inhibits P-glycoprotein (P-gp) in MDR1-MDCKII cells. Isosinensetin has multiple activities such as anti-tumor, anti-viral, anti-inflammatory, and antioxidant effects. Isosinensetin can be used in the research of various diseases including cancer, inflammation, osteoporosis, diabetes, etc.

HY-N1966

(E)-Osmundacetone	Inhibitor	99.88%
(E)-Osmundacetone is the isomer of Osmundacetone. Osmundacetone significantly suppresses the phosphorylation of MAPKs, including JNK, ERK, and p38 kinases. Osmundacetone has a neuroprotective effect against oxidative stress.

HY-P10072A

MK2-IN-5 acetate		98.46%
MK2-IN-5 (Hsp25 kinase inhibitor) acetate is a Mk2 pseudosubstrate (K_i= 8 μM). MK2-IN-5 acetate targets the protein interaction domain in the MAPK pathway. MK2-IN-5 acetate inhibits HSP25 and HSP27 phosphorylation.

HY-141645

IMM-H007	Inhibitor
IMM-H007 (WS070117) is an orally active and potent AMPK (AMP-activated protein kinase) activator and TGFβ1 (transforming growth factor β1) antagonist. IMM-H007 has protective effects in cardiovascular diseases via activation of AMPK. IMM-H007 negatively regulates endothelium inflammation through inactivating NF-κB and JNK/AP1 signaling. IMM-H007 inhibits ABCA1 degradation. IMM-H007 resolves hepatic steatosis in HFD-fed hamsters by the regulation of lipid metabolism. IMM-H007 can be used for the research of nonalcoholic fatty liver disease (NAFLD) and inflammatory atherosclerosis.

HY-14928

Lobeglitazone	Inhibitor
Lobeglitazone is a new type of thiazolidinedione. Lobeglitazone is the orally active agonist for PPAR with EC₅₀ of 137.4 nM and 546.3 nM for PPARγ and PPARα. Lobeglitazone is the inhibitor for ERK/JNK/Smad/NF-κB signaling pathway. Lobeglitazone exhibits anti-inflammatory, anti-diabetic, anti-fibrotic and anti-atherosclerotic properties.

HY-146195

MAPK-IN-1	Inhibitor
MAPK-IN-1 (Compound 2) is a MAPK signaling pathway inhibitor. MAPK-IN-1 exhibits AChE inhibitory activity with an IC₅₀ of 23.84 μM. MAPK-IN-1 shows anti-neuroinflammatory and neuroprotective activity and can be used for Alzheimer's disease research.

HY-10412

CEP-1347	Inhibitor	98.50%
CEP-1347 is an inhibitor of the JNK/SAPK pathway with neuroprotective effects. CEP-1347 blocks JNK1 activation induced by members of the mixed lineage kinase (MLK) family (MLK3, MLK2, MLK1, dual leucine zipper kinase, and leucine zipper kinase). As an inhibitor of MDM4, CEP-1347 can more effectively inhibit the growth of glioma cells expressing wild-type p53.

HY-13326

ASP3026		99.88%
ASP3026 is a selective and orally active inhibitor of anaplastic lymphoma kinase (ALK). ASP3026 is a selective and oral active anaplastic lymphoma kinase (ALK) inhibitor with a IC₅₀ value of 3.5 nM. ASP3026 can inhibit the phosphorylation of IGF-1R, STAT3, AKT and JNK proteins, and induce the cleavage of caspase 3 and PARP. It also inhibited ROS and ACK. ASP3026 can be used in anti-tumor research.

HY-100538A

DTP3 TFA	Inhibitor	98.00%
DTP3 TFA is a potent and selective GADD45β/MKK7 (growth arrest and DNA-damage-inducible β/mitogen-activated protein kinase kinase 7) inhibitor. DTP3 TFA targets an essential, cancer-selective cell-survival module downstream of the NF-κB pathway.

HY-101287

MPT0B392	Activator	99.63%
MPT0B392, an orally active quinoline derivative, induces c-Jun N-terminal kinase (JNK) activation, leading to apoptosis. MPT0B392 inhibits tubulin polymerization and triggers induction of the mitotic arrest, followed by mitochondrial membrane potential loss and caspases cleavage by activation of JNK and ultimately leads to apoptosis. MPT0B392 is demonstrated to be a novel microtubule-depolymerizing agent and enhances the cytotoxicity of sirolimus in sirolimus-resistant acute leukemic cells and the multidrug resistant cell line.

HY-112402

SP 600125, negative control	Control	98.05%
SP 600125，negative control (SPM1) is an alkyl derivative of pyrazoloanthrone，which can be used as a negative control for SP600125 (HY-12041).

HY-N7110

6-Hydroxyflavone	Activator	99.95%
6-Hydroxyflavone is an orally effective flavonoid compound. 6-Hydroxyflavone can inhibit LPS (HY-D1056) -induced NO production and has anti-inflammatory effects. 6-Hydroxyflavone promotes osteoblast differentiation by activating AKT, ERK 1/2 and JNK signaling pathways. 6-Hydroxyflavone has an inhibitory effect on bovine hemoglobin (BHb) glycosylation. 6-Hydroxyflavone has a kidney protective effect. In addition, 6-Hydroxyflavone enhances GABA-induced current through the Benzodiazepine sites of γ-aminobutyric acid (GABA_A) receptors. 6-Hydroxyflavone shows a clear preference for α2 - and α3 - subtypes, which play an anti-anxiety role.

HY-107600

IQ-3	Inhibitor	99.38%
IQ-3 is a specific inhibitor of the c-Jun N-terminal kinase (JNK) family, with preference for JNK3. IQ-3 exhibits K_d values of 0.24 μM, 0.29 μM and 0.066 μM for JNK1, JNK2 and JNK3, respectively.

HY-B0380

Trimebutine	Inhibitor	99.42%
Trimebutine is a multi-target inhibitor and opioid receptor agonist with antimuscarinic activity. Trimebutine inhibits L-type Ca²⁺ channels and large-conductance calcium-activated potassium channels (BK_Ca channels), thereby inhibiting extracellular calcium influx and potassium ion efflux. Trimebutine also targets Toll-like receptors, inhibits Toll-like receptor 2/4/7/8/9 signals, and inhibits LPS-induced IRAK1 activation, as well as ERK1/2, JNK and NF-κB activation, thereby exerting anti-inflammatory effects. Trimebutine also induces tumor cell apoptosis by inhibiting the AKT/ERK pathway. Trimebutine also inhibits excessive contraction of smooth muscle and can be used in the study of gastrointestinal disorders such as irritable bowel syndrome (IBS).

SP600125	JNK1, IC₅₀: 40 nM	JNK2, IC₅₀: 40 nM	JNK3, IC₅₀: 90 nM		99.73%
Anisomycin				JNK	99.82%
JNK-IN-8	JNK1, IC₅₀: 4.7 nM	JNK2, IC₅₀: 18.7 nM	JNK3, IC₅₀: 1 nM		99.67%
Chloramphenicol				JNK	99.93%
Astragaloside IV				JNK	99.93%
Guggulsterone				JNK	99.83%
Tomatidine				JNK	≥98.0%
Isovitexin	JNK1	JNK2			99.82%
JNK Inhibitor VIII	JNK1, Ki: 2 nM JNK1, IC₅₀: 45 nM	JNK2, Ki: 4 nM JNK2, IC₅₀: 160 nM	JNK3, Ki: 52 nM		99.58%
Ginsenoside Re				JNK	99.22%
Tanzisertib	JNK1, IC₅₀: 61 nM	JNK2, IC₅₀: 7 nM	JNK3, IC₅₀: 6 nM		99.87%
CC-90001	JNK1	JNK2			99.75%
JNK-IN-7	JNK1, IC₅₀: 1.5 nM	JNK2, IC₅₀: 2 nM	JNK3, IC₅₀: 0.7 nM		98.92%
Bentamapimod	JNK1, IC₅₀: 80 nM	JNK2, IC₅₀: 90 nM	JNK3, IC₅₀: 230 nM		99.32%
AS601245	hJNK1, IC₅₀: 150 nM	hJNK2, IC₅₀: 220 nM	hJNK3, IC₅₀: 70 nM		98.83%
DB07268	JNK1, IC₅₀: 9 nM				99.92%
D-JNKI-1				JNK	99.29%
CC-401 hydrochloride				JNK, Ki: 25-50 nM	99.35%
TNG348	JNK1				99.74%
BI-78D3				JNK, IC₅₀: 280 nM	99.85%
Seratrodast				JNK	98.86%
SR-3306				JNK	99.0%
Juglanin				JNK	99.90%
Tomatidine hydrochloride				JNK	99.58%
J30-8			JNK3, IC₅₀: 40 nM		99.90%
Indirubin-3′-oxime	JNK1, IC₅₀: 0.8 μM	JNK2, IC₅₀: 1.4 μM	JNK3, IC₅₀: 1 μM		99.10%
TCS JNK 5a		JNK2, pIC₅₀: 6.5	JNK3, pIC₅₀: 6.7		99.40%
Loureirin B				JNK	99.16%
CEP-1347	JNK1				98.50%
MPT0B392				JNK	99.63%
IQ-3	JNK1, Kd: 0.24 μM	JNK2, Kd: 0.29 μM	JNK3, Kd: 0.066 μM		99.38%
JNK3 inhibitor-4	JNK1, IC₅₀: 143.9 nM	JNK2, IC₅₀: 298.2 nM	JNK3, IC₅₀: 1.0 nM		99.37%
L-JNKI-1				JNK	99.01%
JTP10-△-TATi TFA	JNK1, IC₅₀: 1.16 μM	JNK2, IC₅₀: 92 nM	JNK3, IC₅₀: 1.2 μM		98.49%
IQ-1S free acid	JNK1, Kd: 240 nM	JNK2, Kd: 360 nM	JNK3, Kd: 100 nM		99.28%
SR-3576			JNK3, IC₅₀: 7 nM		98.2%
SX 011	JNK1, IC₅₀: > 300 (Pan)	JNK2, IC₅₀: 100 nM			99.33%
JNK-IN-11	JNK1, IC₅₀: 1.8 μM	JNK2, IC₅₀: 21.4 μM	JNK3, IC₅₀: 2.2 μM		98.01%
JNK-IN-13		JNK2, IC₅₀: 500 nM	JNK3, IC₅₀: 290 nM
Salicortin				JNK
JTP10-△-R9 TFA	JNK1, IC₅₀: 1.1 μM	JNK2, IC₅₀: 89 nM	JNK3, IC₅₀: 1.2 μM		99.80%
CC-401				JNK, Ki: 25-50 nM	98.60%
PT109	JNK1, IC₅₀: 0.143 μM	JNK2, IC₅₀: 0.831 μM	JNK3, IC₅₀: 0.285 μM
(-)-Zuonin A	JNK1, IC₅₀: 1.7 μM	JNK2, IC₅₀: 2.9 μM	JNK3, IC₅₀: 1.74 μM		99.99%
Sugiol	JNK1	JNK2			99.88%
IQ-1S	JNK1, Kd: 390 nM	JNK2, Kd: 360 nM	JNK3, Kd: 87 nM
JNK-1-IN-1	JNK1
Aloisine A				JNK, IC₅₀: 3-10 μM
JAK3-IN-13	JNK1, IC₅₀: 4728 nM	JNK2, IC₅₀: 2039 nM	JNK3, IC₅₀: 8 nM
GSK3-IN-10			JNK3, IC₅₀: 2900 nM
Ginsenoside Re (Standard)				JNK
JNK3 inhibitor-7	JNK1, IC₅₀: 1039 nM	JNK2, IC₅₀: 973 nM	JNK3, IC₅₀: 53 nM
Lucidone				JNK
ERK2 IN-5			JNK3, Ki: 550 nM
Cernuumolide J			JNK3
YL5084	JNK1, IC₅₀: 2173 nM	JNK2, IC₅₀: 70 nM	JNK3, IC₅₀: 84 nM
JNK3 inhibitor-5	JNK1, IC₅₀: 82.7 nM	JNK2, IC₅₀: 29.4 nM	JNK3, IC₅₀: 0.379 nM
JNK3 inhibitor-8	JNK1, IC₅₀: >10000 nM	JNK2, IC₅₀: 2203 nM	JNK3, IC₅₀: 21 nM
PROTAC JNK1-targeted-1	JNK1, DC₅₀: 10 nM
MR2938				JNK
JNK3 inhibitor-3	JNK1, IC₅₀: 147.8 nM	JNK2, IC₅₀: 44 nM	JNK3, IC₅₀: 4.1 nM
JNK-IN-14	JNK1, IC₅₀: 1.82 nM	JNK2, IC₅₀: 10.5 nM	JNK3, IC₅₀: 10.5 nM
JNK-1-IN-4	JNK1, IC₅₀: 2.7 nM	JNK2, IC₅₀: 19.0 nM	JNK3, IC₅₀: 9.0 nM
TOPK-p38/JNK-IN-1				JNK
ZG-10	JNK1, IC₅₀: 809 nM	JNK2, IC₅₀: 1140 nM	JNK3, IC₅₀: 709 nM
JNK3 inhibitor-9			JNK3, IC₅₀: 12 nM
JNK-1-IN-5	JNK1
Ophiopogonin B				JNK
Cyy-272	JNK1, IC₅₀: 1.25 μM	JNK2, IC₅₀: 1.07 μM	JNK3, IC₅₀: 1.24 μM
JNK3 inhibitor-2	JNK1, IC₅₀: >100 μM	JNK2, IC₅₀: >100 μM	JNK3, IC₅₀: 0.25 μM

Name
Email *

	Sorry, but the email address you supplied was invalid.

JNK

JNK

JNK Isoform Specific Products:

JNK Isoform Specific Products:

JNK Related Products (275)

Antibodies (16)

JNK Isoform Comparison

JNK Related Products (275):